business
Regenxbio Shares Rise After Positive Duchenne Trial Results
Key takeaways
- Regenxbio reported a first-quarter loss of $1.72 per share, wider than analyst expectations of a $1.34 loss per share.
- Revenue totaled $6.39 million, well below the consensus estimate of $25.8 million.
- The company’s revenue declined 93% year-on-year from $89.0 million in the first quarter of 2025.
Regenxbio Shares Rise After Positive Duchenne Trial Results Fiona Craig Thu, May 14, 2026 at 9:09 PM GMT+7 2 min read RGNX 4516.T medical research 10 ©Pixnio Regenxbio (NASDAQ:RGNX) shares gained more than 4% in premarket trading Thursday after investors focused on encouraging clinical trial results for the company’s Duchenne muscular dystrophy therapy, despite weaker-than-expected quarterly financial results.
Regenxbio reported a first-quarter loss of $1.72 per share, wider than analyst expectations of a $1.34 loss per share.
Revenue totaled $6.39 million, well below the consensus estimate of $25.8 million.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Forbes
Versant Media Group Shares Rise Following Positive Q1 Earnings Report
STAT News
STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
Investing.com
Landsec shares rise as FY26 asset values beat forecasts
STAT News
STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop